Investor Presentaiton

Innovation: 2022-2024 key news flow Regulatory submissions or acceptances Regulatory approvals or other regulatory action Late-stage readouts 10 2022 (Achieved) Priorix MMR¹ (US) Vocabria/Rekambys - HIV (JP) Cervarix - human papillomavirus (CN²) Covifenz³ - COVID-19 vaccine (CA4) Menveo liquid (US) Boostrix (US) Benlysta - Lupus nephritis (CN) Juluca HIV (CN) Rotarix liquid (US) Vidprevtyn Beta COVID-19 vaccine (EU) Shingrix 18+ at increased risk of HZ6 (JP) - daprodustat ASCEND, anaemia of CKD7 (US, EU) momelotinib - MOMENTUM, myelofibrosis (US, EU) Vidprevtyn Beta COVID-19 vaccine (EU) SKYCovione COVID-19 vaccine (EU³) RSV older adults vaccine - ≥60 YoA⁹ (US, EU, JP) cabotegravir (long-acting) pre-exposure prophylaxis (EU, CN) Phase III RSV older adults vaccine - ≥60 YoA Vidprevtyn Beta5 - COVID-19 vaccine SKYCovione COVID-19 vaccine gepotidacin - EAGLE", UUTI¹² H1 H2 도 H1 H2 H1 도 H2 Jemperli¹³ RUBY", IL endometrial cancer Vocabria/Rekambys - SOLAR, HIV Phase II bepirovirsen - B-CLEAR, HBV14 Jemperli³ PERLA, NSCLC15 GSK3640254 - DOMINO and DYNAMIC, HIV20 1. Measles, mumps, and rubella 2. China 3. Partnered with Medicago, Inc. 4. Canada 2023 daprodustat - ASCEND, anaemia of CKD (US, EU) momelotinib - MOMENTUM, myelofibrosis (US) RSV older adult vaccine - ≥60 YoA (US) SKYCovione COVID-19 vaccine (EU³) Shingrix 18+ at increased risk of HZ (JP) RSV older adults vaccine - ≥60 YOA (EU, JP) cabotegravir (long-acting) pre-exposure prophylaxis (EU) Vocabria - HIV treatment (CN) Jemperli¹³ - RUBY11, 1L endometrial cancer (US) 22 Jemperli¹³ - RUBY", IL endometrial cancer (US, EU) mepolizumab- severe asthma (CN) gepotidacin - EAGLE", uUTI (US) mepolizumab - nasal polyposis (CN, JP) gepotidacin - EAGLE", uUTI (EU) MenABCWY vaccine (US) RSV older adults vaccine - 50-59 YoA (US, EU, JP) Blenrep - DREAMM-7, 2L+ MM 16 (US, EU) Blenrep - DREAMM-8, 2L+ MM (US, EU) Phase III MenABCWY vaccine Phase II bepirovirsen - B-TOGETHER, HBV Phase III gepotidacin - EAGLE, GC17 RSV older adults vaccine - 50-59 YoA Blenrep DREAMM-7, 2L+ MM Blenrep-DREAMM-8, 2L+ MM Zejula¹³ - FIRST, IL maintenance OC Phase II MenABCWY vaccine 2nd gen 5. Co-developed with Sanofi 6. Herpes Zoster 2024 Jemperli¹³ - RUBY", IL endometrial cancer (EU) mepolizumab - severe asthma (CN) mepolizumab - nasal polyposis (JP) gepotidacin - EAGLE", uUTI (US, EU) Blenrep - DREAMM-7, 2L+ MM (US, EU) Blenrep - DREAMM-8, 2L+ MM (US, EU) momelotinib - MOMENTUM, myelofibrosis (EU) MenABCWY vaccine (US) RSV older adults vaccine - 50-59 YoA (US, EU, JP) mepolizumab - MATINEE, COPD 18 (US, EU, CN, JP) gepotidacin - EAGLE", uUTI (JP) gepotidacin - EAGLE, GC (US, EU) linerixibat - GLISTEN, cholestatic pruritus in PBC 19 (US, EU) Phase III mepolizumab - MATINEE, COPD linerixibat - GLISTEN, cholestatic pruritus in PBC Zejula13 - ZEAL, IL maintenance NSCLC cobolimab 13 - COSTAR, NSCLC Phase II Pneumococcal 24 valent (MAPS21) paediatric vaccine 7. Chronic Kidney disease 8. Received regulatory approval in South Korea 9. Years of age 10. Late-stage is defined as Phase IIb onwards 11. Interim analysis 12. Uncomplicated urinary tract infection (gepotidacin EAGLE-2 and -3) 13. Tesaro asset 14. Hepatitis B virus 15. Non-small cell lung cancer 16. Multiple myeloma 17. Urogenital gonorrhoea (gepotidacin EAGLE-1) 18. Chronic obstructive pulmonary disease 19. Primary biliary cholangitis 20. Will not progress to Phase III 21. Multiple Antigen Presenting System 22. Subject to US FDA priority review GSK 32

View entire presentation